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Summary Compared to classical chemotherapy, peptide-
based drug targeting is a promising therapeutic approach for
cancer, which can provide increased selectivity and decreased
side effects to anticancer drugs. Among various homing de-
vices, gonadotropin-releasing hormone-III (GnRH-III) pep-
tide represents a suitable targeting moiety, in particular in the
treatment of hormone independent tumors that highly express
GnRH receptors (e.g. colon carcinoma). We have previously
shown that GnRH-III[4Lys(Ac),8Lys(Dau = Aoa)] bioconju-
gate, in which daunorubicin was attached via oxime linkage to
the 8Lys of a GnRH-III derivative, exerted significant in vivo
antitumor effect on subcutaneously developed HT-29 colon
tumor. In contrast, results of the study reported here indicated
that this compound was not active on an orthotopically devel-
oped tumor. However, if Lys in position 4 was acylated with
butyric acid instead of acetic acid, the resulting bioconjugate
GnRH-III[4Lys(Bu),8Lys(Dau = Aoa)] had significant tumor
growth inhibitory effect. Furthermore, it prevented tumor neo-
vascularization, without detectable side effects. Nevertheless, the
development of metastases could not be inhibited by the biocon-
jugate; therefore, its application in combination with a metastasis
preventive agentmight be necessary in order to achieve complete
tumor remission. In spite of this result, the treatment with GnRH-
III[4Lys(Bu),8Lys(Dau = Aoa)] bioconjugate proved to have
significant benefits over the administration of free daunorubicin,
which was used at the maximum tolerated dose.
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Introduction
Colorectal cancer is the third most common type of cancer
worldwide, with nearly 1.4 million new cases diagnosed in
2012. It is predicted that the number of cases will rise to 2.4
million by 2035. About 54 % of colorectal cancer cases occur
in more developed countries, with the highest incidence rate in
Europe [1]. Thus, in addition to colon cancer prevention by
changing nutritional habits [2], the development of efficient
therapeutic strategies is of utmost importance. Peptide-based
targeted tumor therapy, which has been investigated in the last
decades, might be an effective targeted chemotherapeutic ap-
proach to cure colon cancer as well [3]. Nevertheless, only a
few research reports have been published in this field yet [4].
The principle of targeted tumor therapy relies on the struc-
tural and/or functional differences between cancer cells and
healthy ones [5]. One of the possible targeted chemotherapeu-
tic approaches is based on the attachment of an anticancer
drug to a targeting moiety, which recognizes tumor specific
receptors or cell surface structures that are highly expressed on
tumor cells [6]. The homing device conjugated to the chemo-
therapeutic agent enables the specific binding to the tumor cell
surface, without affecting the healthy tissues. Such targeting
moieties could be hormone peptides (e.g. gonadotropin releas-
ing hormone (GnRH), somatostatin, bombesin), whose recep-
tors are highly expressed on many types of tumors, while their
presence on healthy tissues is limited [7].
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In our research, lamprey GnRH-III (Glp-His-Trp-Ser-His-
Asp-Trp-Lys-Pro-Gly-NH2, where Glp is pyroglutamic acid)
has been employed as a key molecule for drug targeting [8]. It
has been found that GnRH-III binds to tumoral GnRH recep-
tors (GnRH-R), while its endocrine effect in mammals is mar-
ginal [9, 10]. Thus, hormonal side effects in case of targeted
tumor therapy using GnRH-III as a homing device are expect-
ed to be insignificant, this feature being important in the treat-
ment of hormone independent tumors like colorectal cancer.
Considering that lysine in position 8 of GnRH-III can be used
for drug conjugation, this amino acid has been used in our
previous studies for the attachment of daunorubicin (Dau)
via oxime linkage. For this purpose, the side chain of Lys
was modified with an aminooxyacetyl (Aoa) group [11].
Aoa was coupled to the ε-amino group either directly or
through a GFLG tetrapeptide spacer cleavable by Cathepsin
B, enzyme known to be overexpressed in cancer cells. These
bioconjugates exerted significant antitumor activity both in
vitro and in vivo. Moreover, no signs of toxicity were detected
on BDF-1 healthy female mice at a dose up to 30 mg Dau
content/kg [12]. Murine C26 colon cancer bearing Balb/c
mice (subcutaneously implanted tumors) were treated with
the bioconjugates at a dose of 15 mg Dau content/kg.
Compared to the untreated control group, longer survival
and about 30–40 % tumor growth inhibition could be
achieved. The in vivo antitumor effect of the bioconjugates
was more pronounced on human HT-29 colon cancer bearing
SCID mice (s.c. implanted tumor), the tumor growth inhibi-
tion being 40–50 % in this case [12]. However, if the C26
tumor was orthotopically developed in Balb/Cmice, the effect
of the bioconjugates on tumor growth was lower than 10 %.
Therefore, more potent analogues were developed [13]. It has
previously been reported that Ser in position 4 could be ex-
changed by Lys or Lys(Ac) without losing the antitumor ac-
tivity of GnRH-III analogs [14]. The replacement of Ser by
Lys(Ac) in the Dau containing bioconjugate led not only to
increased in vitro and in vivo antitumor effect, but also to
enhanced enzymatic stability and cellular uptake. The
GnRH-III[4Lys(Ac),8Lys(Dau = Aoa)] bioconjugate exerted
50 % growth inhibition of orthotopically developed C26 tu-
mor. This promising result prompted us to further develop
short chain fatty acid containing derivatives [15]. The rational
of this drug design strategy was that short-chain fatty acids
(SCFAs), in particular butyrate, which is produced by anaer-
obe bacterial fermentation of dietary fiber within the large
colon, are known for their potential to act as chemopreventive
agents by slowing the cell growth and activating apoptosis in
colon cancer cells [16]. From all prepared SCFA-modified
bioconjugates, the most potent one on HT-29 human colon
cancer cells was GnRH-III[4Lys(Bu),8Lys(Dau = Aoa)], in
which Lys in position 4 was acylated with butyric acid (Fig.
1). Its IC50 value was 2.2 ± 0.6 μM, while this value was
7.4 ± 2.6 μM in the case of acetylated version. The reasons
for the higher in vitro antitumor effect of the butyrated bio-
conjugate were extensively discussed in one of our previous
reports [15]. In brief, it was found that both compounds, sim-
ilarly to the other SCFA containing bioconjugates, were rather
hydrophilic and no significant difference between their
octanol-water partition coefficient and membrane permeabili-
ty could be determined using lipid Langmuir monolayer.
Therefore, secondary structure analysis by circular dichroism
(CD) spectroscopy was further performed. However, the CD
spectra of the bioconjugates did not show any difference. The
binding of the bioconjugates to the GnRH receptor was also
investigated and indicated higher affinity in the case of the
butyrated bioconjugate. It has been reported that the N- and
C-terminal domains of GnRH derivatives play an important
role in the receptor binding. In contrast to the U-shape of
GnRH-I, GnRH-III adopts an extended structure resulting in
lower binding affinity to the type I GnRH receptor [17]. We
assume that the replacement of Ser in position 4 by an acylated
lysine provides a more suitable structure for receptor binding,
which is stabilized more by a larger fatty acid chain, such as
butyric acid. However, the fatty acid chain should not be too
large, so that to negatively affect the binding of the N-terminus
to the receptor. This is a possible explanation why the modi-
fication of 4Lys with butyric acid provides optimal features in
the case of oxime bond-linked Dau-GnRH-III bioconjugates.
Furthermore, we demonstrated by LC-MS that the apoptosis
inducing agent butyric acid was released from the bioconju-
gate in the presence of lysosomal homogenate. It was also
indicated that the oxime bond-linked daunorubicin-GnRH-
III derivative bioconjugates are stable for at least 24 h in
human serum [13, 18]. On the basis of these results, the
in vivo tumor growth inhibitory effect of GnRH-
III[4Lys(Bu),8Lys(Dau = Aoa)] has further been evaluated
on colon carcinoma bearing mice, in comparison with that of
Fig. 1 Structure representation of daunorubicin-GnRH-III derivative
bioconjugates
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Daunorubicin-GnRH-III derivative bioconjugates were pre-
pared by a combination of solid phase peptide synthesis and
chemoselective ligation (e.g. oxime bond formation) as previ-
ously described [13, 15]. The bioconjugates were purified by
RP-HPLC using a mixture of 0.1 % TFA/water and 0.1 %
TFA/MeCN-water (80:20, v/v). The freeze-dried bioconju-
gates, without changing the tfa counter ions, were used in
the in vivo studies, in order to evaluate their tumor growth
inhibitory effect on colon carcinoma bearing mice.
NSG mice
The immunodeficient NSG (Non Obese Diabetic Severe
Combined ImmunoDeficient interleukine Gamma receptor
chain knock-out) (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice
were originated from Jackson Laboratories. The mice were
held in filter-top boxes in the experimental barrier rooms
and every box-opening was done under a Class 100 laminar-
flow hood by an operator dressed in sterilized surgical attire.
The animal housing density was in accordance with the inter-
national recommendations. The cage components, corn-cob
bedding and food (VRF1 from Special Diet Services) were
steam-sterilized in autoclave (121 °C, 20 min). The distilled
water was acidified to pH 3 with hydrochloric acid.
The animals used in these studies were cared for according
to the BGuiding Principles for the Care and Use of Animals^
based upon the Helsinki declaration, and they were approved
by the local ethical committee. Our permission for breeding
and performing experiments with laboratory animals is valid
until 2020/10/12 (registration numbers: 22.1/772/3/2010 and
PEI/001/2574–6/2015).
Study of the chronic toxicity
NSG adult male mice, weighing 26–34 g, were used.
Daunorubicin was dissolved in distilled water at a concentra-
tion that allowed the dose to be given in a volume of 0.1 mL/
10 g body weight. In this experiment, each group consisted of
3 mice, which were treated by intraperitoneal (i.p.) adminis-
tration on days 1, 4, 8, 12 and 16. The toxicity was assessed on
the basis of lifespan and body weight and the survival time
was followed for 20 days.
Development of the primary tumor
Female NSGmice, weighing 24–28 g, were used in this study.
The xenografts were established by subcutaneous injection of
ca. 106 HT-29 (GnRH receptor positive) human colon carci-
noma cells, which were fromATCC and cultured according to
their standards. The mice with palpable tumors were killed by
cervical-dislocation, disinfected with iodine, and the subcuta-
neous tumor was dissected out aseptically. Tumor pieces of 2–
3 mm3 were transplanted under aseptic conditions,
orthotopically, into narcotized NSG mice.
Tumor transplantation
For direct implantation, mice were anesthetized (narcotic mix-
ture: tiletamine, zolazepam, xylazine, butorphanol) and the
abdomen was sterilized with iodine and alcohol swabs. A
small midline incision (0.5 cm) was made and the colorectal
part of the intestine was exteriorized. Serosa of the site where
the tumor pieces were to be implanted was removed. A piece
of 2 mm3 HT-29 human colon tumor was implanted on the top
of the animal intestine; an 8/0 surgical (polypropylene) suture
was used to suture it on the wall of the intestine. The intestine
was returned to the abdominal cavity and the abdominal wall
was closed with 4/0 surgical (polyglycolic acid) sutures. The
wound was sterilized with iodine and alcohol swab again and
the animals were kept in a sterile environment. For pain re-
lease and rehydration, mice were treated s.c. with 100 mg/kg
algopyrine in Ringer solution containing 5 % glucose. On the
next day, no signs of pain and stress of mice were observed.
Doses and treatments
Based on the results of the chronic toxicity study, we used
only 1 mg (1.773 μmol)/kg free Dau, weekly, in the Dau
treated group. Thirteen treatments were applied from the day
5 after tumor transplantation until the day 50 in the groups
treated with the bioconjugates (every Monday and Thursday).
The treatments were performed by i.v. (intravenous) or i.p.
administration; the compounds were dissolved in distilled wa-
ter (0.1 mL/10 g body weight).
In this experiment, 7 mice/group were used for the treatment
with the bioconjugates (GnRH-III[4Lys(Ac),8Lys(Dau = Aoa)]
and GnRH-III[4Lys(Bu),8Lys(Dau = Aoa)]) as well as in the
control group.
The bioconjugates were administered at different doses
during the treatment period. In the first five treatments, they
were i.v. administered, at a dose of 28.435 μmol/kg body
weight (15 mg Dau content in the bioconjugate/kg). From
the 6th to the 13th treatment, they were i.p. administered at a
dose of 14.217 μmol/kg body weight (7.5 mg Dau content in
the bioconjugate/kg). The first five doses represented the ini-
tial round of treatments, which was followed by the
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maintenance therapy. In the maintenance treatments, 5 % glu-
cose solution instead of distilled water was used, in order to
minimize the harmful effects of tfa salts that were present in
the lyophilized bioconjugates.
The mice from all groups were sacrificed by deadly over-
slept cocktail (0.3 mL/mouse concentrated nembutal
(pentobarbitone) solution), on day 50 after tumor
transplantation.
After that, the tumors were removed and the tumor weight
was determined in all cases.
Statistical analysis
The statistical analyses were performed by Medcalc® version
12.1.3.0. (Broekstraat 52, B-9030 Mariakerke, Belgium)
using the non-parametric Mann-Whitney (independent sam-
ples) test. The experimental data were filtered by Gaussian
statistics g. P-values lower than 0.05 were considered statisti-
cally significant.
Routine histological examination
The removed and fixed tissue samples were dehydrated in a
graded series of ethanol, infiltrated with xylene and embedded
into paraffin. Histological sections were stained with Harris
hematoxylin and eosin (10:1, v/v, 1 % solutions) in acidified
70 % ethanol and mounted. The histological samples were
examined under a light microscope (Olympus CH30,
Olympus Optical, Japan).
Determination of the proliferative index
and vascularization in orthotopic HT-29 tumor tissues
Before ending the experiment (30 min prior to sacrificing the
mice), the tumor bearing animals were injected i.p. with 5-
bromo-2 V-deoxyuridine (BrdU, 200 mg/kg; Sigma-Aldrich
Kft, Budapest, Hungary). After 6 h, 5–7 μm thick tissue sec-
tions were excised from the newly frozen tumors and used for
the detection of BrdU positive cells using an anti-BrdUmono-
clonal antibody (Becton Dickinson Hungary Kft., Budapest,
Hungary), according to the manufacturer’s protocol. Positive
cells were visualized with TRITC-conjugated anti-mouse IgG
(1:100, Sigma). Endothelial cells were distinguished from tu-
mor cells by treating the samples with rat anti-mouse CD31
antibody and labelled with biotinylated anti-rat IgG and
streptavidin-FITC (Vector Laboratories, Burlingame, CA).
The nuclei were stained with the Hoechst 33,342 dye
(Molecular Probes, Eugene, OR). The number of labelled
HT-29 tumor cells and the quantity of CD31-positive samples
were determined in two different tumors by microscopic anal-
ysis of 6 independent regions. The vascularization extent of
primary tumors was determined by microscopic analysis of
two different living tumors, where four independent areas of
living cells were counted and the percentage of separated en-
dothelial cells covering a 10× magnification field of vision
was calculated [12].
Results
Chronic toxicity of daunorubicin on NSG healthy mice
Before starting the treatment of tumor bearing mice, the toler-
able dose of daunorubicin was tested on NSG healthy mice.
Daunorubicin hydrochloride was i.p. administered at a dose of
1 or 2 mg/kg body weight, on days 1, 4, 8, 12 and 16. In both
cases, a significant loss of weight of the animals was observed.
Furthermore, 2 of 3 mice died on day 13 after the fourth
treatment in the group treated with 2 mg/kg dose. The first
animal died in the group treated with 1 mg/kg dose on day 20,
when the experiment was stopped. The body weight of the
animals decreased from ~30 g to ~20 g during this time
(Fig. 2). Therefore, we decided to administer daunorubicin
once a week at a dose of 1 mg/kg.
Tumor growth inhibition
HT-29 human colon tumor (2 mm3) was orthotopically im-
planted on the intestine of mice. The beginning of tumor
growth was controlled on two sacrificed animals and the treat-
ments with the free drug and bioconjugates started on day 5
after tumor implantation.
Mice were treated i.v. with daunorubicin once a week at a
dose of 1 mg (1.773 μmol)/kg. Seven injections were carried
out until the day 50, when the study was finished. The bio-
conjugates were administered twice a week. The first five
injections represented the initial round of treatments using
28.435 μmol/kg body weight (15 mg Dau content in the bio-
conjugate/kg), while half of this amount (14.217 μmol/kg
body weight; 7.5 mg Dau content) was applied in further eight
administrations as maintenance therapy. After the fifth i.v.
injection with the bioconjugates, the tail inflammation was
observed; therefore, the treatments continued by i.p. adminis-
tration. The mice were sacrificed on the day 50 after tumor
implantation and the tumors were removed, followed by mea-
suring their weight (Fig. 3). In comparison with the
control group (7 animals), about 30 % tumor growth
inhibition was observed in the group (7 animals) treated
with free daunorubicin. In contrast to our previous study
in which s.c. implanted C26 tumor was used, the
GnRH-III[4Lys(Ac),8Lys(Dau = Aoa)] bioconjugate ex-
hibited very moderate, not significant tumor growth inhibition
(only ~7 % to the control group). In contrast, the GnRH-
III[4Lys(Bu),8Lys(Dau = Aoa)] bioconjugate exerted a signif-
icant inhibitory effect on tumor growth, leading to ~40 %
inhibition in average compared to the control (Fig. 3).
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Liver- and cardiotoxicity of free daunorubicin
and its GnRH-III derivative bioconjugates
Macroscopic toxic side effects of daunorubicin and its GnRH-
III derivative bioconjugates were assessed after completing
the treatments of mice. The liver toxicity was evaluated by
determining the weight of the liver. The average liver weight
of mice treated with the free drug decreased with about 11 %,
difference which was not significant to the control group.
Slight liver weight enhancement (2 % and 5 % in case of the
acetylated and butyrated bioconjugates, respectively) was ob-
served after the treatments with the bioconjugates (Fig. 4). The
cardiotoxicity was assessed on the basis of histological exam-
ination using hematoxylin and eosin stain of tissue slides [19].
Considering that no changes indicating heart failure were ob-
served by light microscopy, in comparison with the control
group, further studies of other biomarkers for heart diseases
were not investigated. Similar to the liver, in any of the treated
animals there was nomacroscopically observed tissue damage
of heart that would indicate cardiotoxicity. Therefore, we
could conclude that neither the bioconjugates nor the free
daunorubicin showed any liver- or cardiotoxicity at the ap-
plied doses.
Macroscopic metastases in treated and untreated mice
The tumor metastases on different organs (liver, lung, spleen,
lymph node, pancreas, diaphragm and kidney) were also in-
vestigated in the present study. The results summarized in
Table 1 indicated that neither the free drug nor the bioconju-
gates had significant influence on the global metastasis.
However, the tumor was less spread out on several organs in
the case of treated animals compared to the untreated ones.
Liver metastasis was observed in each case. The lung was also
Fig. 2 Chronic in vivo toxicity of
daunorubicin on NGS mice
Fig. 3 In vivo antitumor effect of Dau-GnRH-III derivative bioconju-
gates and free daunorubicin on HT-29 orthotopic primary human colon
carcinoma (Mean ± SD, Mann-Whitney test)
Fig. 4 Macroscopic liver toxicity of Dau-GnRH-III derivative bioconju-
gates and free daunorubicin (Mean ± SD)
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invaded by tumors almost in all tested animals. The observed
metastases on spleen were not significant in any group.
Significant improvement in preventing metastasis was detect-
ed on pancreas and lymph nodes in the treated groups com-
pared to the control. The improvement on the latter one was
more pronounced when the animals were treated with the
bioconjugates. However, the diaphragm was more affected
by tumors , pa r t i cu l a r l y in the case o f GnRH-
III[4Lys(Ac),8Lys(Dau = Aoa)] treated mice.
Tumor proliferation and vascularization
Compared to the control animals, the proliferation rate of
orthotopically developed HT-29 tumors did not significantly
decrease in the groups treated with the bioconjugates (~15 %)
(Fig. 5). Nevertheless, this effect was not observed at all on
Dau treated animals.
In contrast to the proliferation index, the tumor vasculari-
zation (vessel density) in mice treated with the bioconjugates
was considerable lower (ca. 35 %) compared to the controls
(Fig. 6). Furthermore, the treatment with the free drug in-
creased the number of newly formed blood vessels.
Discussion
Colon cancer is one of the most widespread types of cancer in
developed countries; therefore, development of efficient treat-
ment procedures is necessary. Targeted tumor therapy is a
promising approach to treat different types of cancer without
significant side effects. Among homing devices that might be
used for drug targeting, hormone peptides like GnRH or so-
matostatin are highly promising. These peptides have own
antiproliferative effect, which could enhance the activity of
the targeted drug molecules. At present, some of these biocon-
jugates are under clinical investigations [20].
In our research, GnRH-III peptide was mainly employed as
a targeting moiety, due to its low endocrine effect in mammals
and significant antiproliferative effect on different types of
cancer cells. Our previous results showed that bioconjugates
Table 1 Metastasis on different organs

















































Fig. 5 Proliferation index of HT-29 orthotopic primary human colon
carcinoma treated with Dau-GnRH-III derivative bioconjugates or dau-
norubicin (Mean ± SD)
Fig. 6 Vascularization of HT-29 orthotopic primary human colon carci-
noma treated with Dau-GnRH-III derivative bioconjugates or daunorubi-
cin (Mean ± SD, Whitney test)
(Px = free Dau treated group vs. bioconjugate treated group)
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in which daunorubicin was attached to the side chain of Lys in
position 8 via oxime linkage exerted significant antitumor
effect both in vitro and in vivo. However, the efficacy of the
bioconjugates was highly dependent on the tumor type and
whether this was subcutaneously or orthotopically developed
in mice. Orthotopically developed tumors represent the native
conditions much better than the subcutaneously implanted
ones. In this case, also the tumor metastases and the vascular-
ization of primary tumors could occur easier than those of
isolated s.c. implanted tumors. Therefore, in the present study,
HT-29 human colon tumor was implanted on the intestine of
immunodeficient NSG mice. Two Dau-GnRH-III derivative
bioconjugates that showed high antitumor activity in vitro
were selected for the treatment. These compounds contained
a GnRH-III derivative in which Ser in position 4 was modified
by Lys acylated with acetic or butyric acid (Fig. 1). These
bioconjugates were not toxic on mice up to 30 mg daunoru-
bicin content/kg body weight. However, the maximum toler-
ated dose of free daunorubicin was 1–2 mg/kg/week in immu-
nodeficient tumor bearing mice. According to the in vivo
chronic toxicity study, we used only 1 mg/kg free Dau, week-
ly. In contrast to this, the bioconjugates were administered two
times per week, at a dose of 15 mg Dau content in bioconju-
gate/kg, five times as initial treatment and then 7.5 mg for the
maintenance treatment. The results of this study indicated that
the acetylated version of Dau-GnRH-III bioconjugate had no
effect on this type of tumor (Fig. 3). Interestingly, it has pre-
viously shown significant antitumor effect (50 % tumor
growth inhibition) on an orthotopically developed C26 mouse
colon tumor [14]. A possible explanation of this result might
be the difference in the doubling time of cancer cells. The C26
tumor is an aggressive and fast proliferating tumor type, while
HT-29 grows much slower. In contrast to this, the butyric acid
modified bioconjugate exerted higher tumor growth inhibition
than the free daunorubicin (40 % and 30 % to the control,
respectively). The increased tumor growth inhibition of
GnRH-III[4Lys(Bu),8Lys(Dau = Aoa)] compared to GnRH-
III[4Lys(Ac),8Lys(Dau = Aoa)] might partially be explained
by the higher receptor binding affinity and cellular uptake of
the butyrated version, as determined in previous in vitro
studies [15].
The toxic side effects of daunorubicin and bioconjugates
on different organs were also evaluated. Particular interest was
in determining the liver and heart toxicity, because of the well
known cardiotoxity of anthracyclines. Except for a moderate
(11 %) liver shrinkage in the case of daunorubicin treatment
(Fig. 4), neither the bioconjugates nor the free daunorubicin
showed any toxicity at the applied doses.
The number of dividing cells in tumor tissues as well as the
tissue vascularization are important factors of tumor growth.
Therefore, the proliferative index was calculated and the new-
ly formed blood vessels in the tumor were counted. In the case
of mice treated with the bioconjugates, the proliferative index
was lower than that of control animals and mice treated with
the free drug. However, the decrease was not significant.
Interestingly, the number of blood vessels was considerably
lower in the case of mice treated with the bioconjugates (64–
67 % to the control), while a slightly increased number was
observed in the case of daunorubicin treated animals (112 %).
This might explain the higher tumor growth inhibition in-
duced by the bioconjugate and could be an important aspect
in its beneficial effect over the application of the free drug.
In conclusion, we clearly showed that GnRH-
III[4Lys(Bu),8Lys(Dau = Aoa)] bioconjugate, in which dauno-
rubicin was attached via a stable oxime linkage to 8Lys and
Ser in position 4 of the homing peptide was replaced by
Lys(Bu), provided benefits over the free drug in the treatment
of colon carcinoma. This bioconjugate exerted significantly
higher tumor growth inhibitory effect on orthotopically devel-
oped human HT-29 colon cancer bearing mice than the free
Dau at the maximum tolerated dose. Furthermore, the biocon-
jugate slightly decreased the tumor proliferation index and
reduced the vascularization of tumor tissues at a high level.
The bioconjugate did not show toxic side effects; however,
similarly to the free drug it was not able to prevent metastases
on different organs.
Taken together these results, we can conclude that GnRH-
III[4Lys(Bu),8Lys(Dau = Aoa)] bioconjugate is a promising
candidate for targeted chemotherapy of colon cancer.
However, its combination with a metastasis preventing agent
might be necessary and should be investigated in future
studies.
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